RxSight, Inc. (RXST)

Market Cap	584.28M
Revenue (ttm)	139.93M
Net Income (ttm)	-27.46M
Shares Out	40.49M
EPS (ttm)	-0.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,068,889
Open	14.53
Previous Close	14.53
Day's Range	14.40 - 14.53
52-Week Range	13.50 - 66.54
Beta	1.25
Analysts	Buy
Price Target	38.50 (+166.62%)
Earnings Date	May 7, 2025

About RXST

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 498
• Stock Exchange: NASDAQ
• Ticker Symbol: RXST
• Website: https://www.rxsight.com

Financial Performance

In 2024, RxSight's revenue was $139.93 million, an increase of 57.09% compared to the previous year's $89.08 million. Losses were -$27.46 million, -43.52% less than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for RXST stock is "Buy." The 12-month stock price forecast is $38.5, which is an increase of 166.62% from the latest price.

Price Target

$38.5

(166.62% upside)

Analyst Consensus: Buy